论文部分内容阅读
本文采用放射免疫分析法，对３０例充血性心力衰竭（ＣＨＦ）患者血浆亮氨酸脑啡肽（下简称ＬＥＫ）、β－内啡肽（下简称β－Ｅｐ）的含量进行检测，并与２０例正常人作对照。结果表明，ＣＨＦ患者血浆ＬＥＫ、β－Ｅｐ显著高于正常对照组（Ｐ均＜０．０１），血浆β－Ｅｐ除心功能ＩＩ级组与正常对照组间无显著差异外（Ｐ＞０．０５），其余各组间均有显著性差异。心力衰竭纠正后，血浆ＬＥＫ、β－Ｅｐ含量明显下降（Ｐ分别＜０．０２和０．０１）。结果提示，内源性阿片样肽ＬＥＫ、β－Ｅｐ参与了ＣＨＦ的病理生理过程；测定血浆ＬＥＫ、β－Ｅｐ含量可作为诊断ＣＨＦ的辅助指标；血浆ＬＥＫ、β－Ｅｐ浓度的变化与心力衰竭患者的病因无关；血浆β－Ｅｐ浓度在一定程度上可反映心力衰竭程度。
In this paper, radioimmunoassay was used to detect the content of leucine enkephalin (LEK) and β-endorphin (beta-Ep) in 30 patients with congestive heart failure (CHF) Twenty normal controls were used as controls. The results showed that the levels of plasma LEK and β-Ep in CHF patients were significantly higher than those in normal controls (all P <0.01), but there was no significant difference between plasma beta-Ep levels and cardiac function in patients with CHF. 05), the rest of the groups were significantly different. Corrected heart failure, plasma LEK, β-Ep levels decreased significantly (P <0.02 and 0.01, respectively). The results suggest that the endogenous opioid peptide LEK, β-Ep involved in the pathophysiology of CHF; determination of plasma LEK, β-Ep content can be used as a secondary indicator of diagnosis of CHF; changes in plasma LEK, β-Ep concentration and heart failure The etiology of the patient has nothing to do; plasma β-Ep concentration to a certain extent, reflect the degree of heart failure.